艾科诺 – 致力于成为生命科学诊断行业先进工具提供者

In China For Global

Focus On Sample-To-Answer
Molecular Diagnostics Solutions

Accurate, Rapid, and Fully Automated

• Sample-To-Answer with No Manual Operations
• Universal Platform with Gold Standard Technologies
• Flexible and Versatile; Allows Mixture of Different Types and Tests in the same batch
• Various Designs for Cross-Contamination Prevention

• CE Mark
• Multiplex RT-PCR
• One sample / One Reaction / Three pathogens

Respiratory Tract Infections

Women’s and Sexual Health

Gastrointestinal Infections

News

2022年3月18日

DXcellence12, a Fully Automated Sample-to-Answer Molecular Diagnostics Platform from Accunome Sciences, Received NMPA Approval of Class III Registration in China

News

Fully Automated Sample-to-Answer Molecular Diagnostics Platform (DXcellence12) and Three Diagnostics Kits from Accunome Sciences Have Obtained CE Mark Certification

News

Accunome Science Has Raised A Total of More Than 100 million RMB of Financing to Accelerate Its Commercialization

News

Respiratory Tract Infections

Women’s and Sexual Health

Gastrointestinal Infections

News

DXcellence12, a Fully Automated Sample-to-Answer Molecular Diagnostics Platform from Accunome Sciences, Received NMPA Approval of Class III Registration in China

Fully Automated Sample-to-Answer Molecular Diagnostics Platform (DXcellence12) and Three Diagnostics Kits from Accunome Sciences Have Obtained CE Mark Certification

Accunome Science Has Raised A Total of More Than 100 million RMB of Financing to Accelerate Its Commercialization

Accunome Sciences was Ranked As one of “The Top 50 Most Promising Startups in 2021“ by Silicon Valley media “The Information”

About ACCUNOME

Products

News

Contact us